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Spinal cord injury (SCI) is a common cause of mortality and neurological morbidity.
Although progress had been made in the last decades in medical, surgical, and
rehabilitation treatments for SCI, the outcomes of these approaches are not yet ideal.
The use of cell transplantation as a therapeutic strategy for the treatment of SCI is very
promising. Cell therapies for the treatment of SCI are limited by several translational
road blocks, including ethical concerns in relation to cell sources. The use of iPSCs is
particularly attractive, given that they provide an autologous cell source and avoid the
ethical and moral considerations of other stem cell sources. In addition, different cell
types, that are applicable to SCI, can be created from iPSCs. Common cell sources
used for reprogramming are skin fibroblasts, keratinocytes, melanocytes, CD34+ cells,
cord blood cells and adipose stem cells. Different cell types have different genetic and
epigenetic considerations that affect their reprogramming efficiencies. Furthermore, in
SCI the iPSCs can be differentiated to neural precursor cells, neural crest cells, neurons,
oligodendrocytes, astrocytes, and even mesenchymal stromal cells. These can produce
functional recovery by replacing lost cells and/or modulating the lesionmicroenvironment.
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INTRODUCTION
Traumatic SCIs result in devastating disability for over one million people in North America alone.
With direct lifetime costs exceeding $1.1–4.6millionUSD per patient, the importance of developing
an effective regenerative treatment for SCI cannot be overstated (National Spinal Cord Injury
Statistical Center, 2014). Cell-based therapies are an exciting strategy to address this pressing need.
Unfortunately, there is no readily accessible source of autologous primary CNS cells, and embryonic
stem cells (ESCs) have a diminishing role given limited supplies and ethical concerns. As a result,
induced pluripotent stem cells (iPSCs) have emerged as a promising approach given their potential
to generate autologous iPSCs and the virtually limitless supply available for research and treatment
(Ahuja and Fehlings, 2016). This article provides a primer on the challenging pathophysiology of
SCI and highlights key iPSC-based techniques with the greatest potential for translation over the
coming decade.
PATHOPHYSIOLOGY
SCI has a unique pathophysiology characterized by an initial traumatic insult (primary injury)
followed by a rapid and progressive secondary injury cascade which generates further permanent
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damage (Choo et al., 2007; LaPlaca et al., 2007). Early cell
death occurs due to cell permeabilization, ischemia, and an
overwhelming increase in pro-apoptotic signaling. This is
compounded by disruption of the sensitive blood-spinal cord
barrier leading to a marked influx of peripheral inflammatory
cells, pro-inflammatory cytokines, and fluid shifts causing spinal
cord swelling (Mautes et al., 2000; Whetstone et al., 2003). Over
the following hours, by-products of cell necrosis (DNA, ATP,
glutamate) are released into the microenvironment leading to
further cell death and activation of pro-inflammatory microglia.
Together, this leads to en masse infiltration of macrophages
and additional microglia which generate cytotoxic reactive
oxygen species as they phagocytose debris. Neutrophils and later
lymphocytes also infiltrate the normally immune-privileged cord
parenchyma and cyclically add to the inflammatory response
(Waxman, 1989; Ulndreaj et al., 2016).
Over the subsequent weeks to months, inflammation begins
to subside leaving a severely disrupted neural and structural
architecture. Loss of oligodendrocytes results in segments of
demyelinated and dysfunctional tracts which begin to die back
from the site of injury. Neurons attempt to regenerate but
are impeded by an interwoven network of hyperproliferative
astrocytes, known as the glial scar, which surround the
lesion epicenter. The normal extracellular matrix now also
contains dense deposits of chondroitin sulfate proteoglycan
(CSPGs) which form a formidable barrier to neurite outgrowth.
Furthermore, the loss of tissue volume leads to the formation of
microcystic cavitation which coalesces into large regions devoid
of an extracellular substrate for migration and growth. While the
lesion continues to develop over years, attempts at regeneration
by endogenous cells are severely hindered by these barriers
(Figure 1; Ahuja et al., 2016).
These harsh post-injury conditions have been a challenge
for cell-based regenerative therapies making optimization of the
transplanted cells critical to success.
CELL THERAPY FOR SCI
Numerous pluripotent and multipotent cell types have been
investigated in SCI. The therapeutic potential of each varies
depending on their cellular behavior, post-transplantation
survival and proliferation, and unique differentiation profile. The
purported mechanism of action for each cell type also differs
but generally they fall into broad categories of regeneration of
lost neurons, remyelination of axons, trophic support, immune
modulation, modification of the extracellular environment, or
a combination thereof (Tobias et al., 2003; Tetzlaff et al.,
2011; Vawda et al., 2012). Importantly, the partially or fully
differentiated progeny of iPSCs act through all of these
mechanisms depending on the cell type, highlighting the broad
utility of the technology.
INDUCED PLURIPOTENT STEM CELLS
Isolation and expansion of multipotent and differentiated
autologous cells is difficult and time consuming. Furthermore,
there is no readily accessible source of autologous CNS cells.
For this reason, many cell-based therapies have utilized ESCs,
however, limited supplies and ethical concerns have been a
significant challenge with this option. Induced pluripotent stem
cells (iPSCs) were generated by Yamanaka and colleagues in 2006
(Takahashi and Yamanaka, 2006). They showed that pluripotent
stem cells, with properties similar to ESCs, could be generated
from mouse fibroblasts by the simultaneous introduction of four
factors (Oct4, Sox2, Klf2, and c-Myc; Takahashi and Yamanaka,
2006). In 2007 they reported that a similar approach could
be used to generate human iPSCs from human fibroblasts
(Takahashi et al., 2007). Concurrently, James Thomson’s group
reported on the generation of human iPSCs with an alternative
combination of factors including Oct4, Sox2, Nanog, and Lin28
(Yu et al., 2007). Together, this work heralded a new age in stem
cell research for SCI as supplies were limitless, adult-derived, and
could potentially be made autologous.
GENERATING iPSCS
Since the introduction of iPSCs, numerous protocols utilizing
different combinations of transcription factors with varying
efficiency rates have been published (Zhao et al., 2008;Meng et al.,
2012). A key to translation is to ensure that the generation of
iPSCs is robust, consistent, and safe. Several labs are currently
optimizing iPSC protocols, including choice of transcription
factor and route of delivery (e.g., viral, plasmid, etc.), to allow the
cells to be used for clinical trials. This requires a balance between
efficiency of generation and safety. For example, most preclinical
protocols employ the proto-oncogene c-Myc, however, this
would be highly concerning in clinical use given its prominent
role in breast, ovarian, colorectal, pancreatic, and gastric cancers
(Chen et al., 2014). As a result, other factors need to be used
which thus far have resulted in lower reprogramming efficiency
(Nakagawa et al., 2008).
The method used to introduce transcription factors into the
cells is also important for clinical translation. Traditionally,
lentivirus has been the vector of choice, however, integration
of lentiviral DNA into actively replicating regions of the host
genome presents safety concerns. Other viruses such as Sendai
Virus and (Ban et al., 2011) adenovirus (Zhou and Freed, 2009)
have also been used with potentially lower risks but much
lower efficacy. As a result, several non-viral methods have been
developed and validated for induction of pluripotency including
Episomal vectors (Subramanyam et al., 2011), recombinant
proteins (Yu et al., 2009), mRNAs (Kim et al., 2009), micro-RNAs
(Warren et al., 2010), and removable transposons (e.g., piggyBac;
Woltjen et al., 2009; Figure 1).
OPTIMIZING THE SOURCE OF iPSCS FOR
SCI
Several somatic cell types have been used to successfully
produce iPSCs including fibroblasts, keratinocytes, melanocytes,
CD34+ cells, hepatocytes, umbilical cord blood cells, and
adipocytes. While the resultant iPSCs all display the hallmarks
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FIGURE 1 | Different types of cells have been used to produce iPSCs, including fibroblasts, keratinocytes, melanocytes, CD34+ cells, cord blood cells,
and adipose stem cells. These somatic cells can be reprogrammed to pluripotent state using viral methods, microRNA, transfection of reprograming proteins,
episcopal vectors and integrating vectors. The collective term for the resultant cells is induced pluripotent stem cells.
of pluripotency, epigenetic modifications within the somatic cell
of origin are retained even in the induced pluripotent state
termed “epigenetic memory.” These modifications, including
DNA methylation, histone acetylation, histone phosphorylation,
and many others, result in a preference of iPSCs to follow the
cell of origin in both gene expression and differentiation profile
(Kim et al., 2011). For example, human keratinocyte-derived
iPSCs have a higher tendency to differentiate to NPCs than less-
invasively obtained CD34+ cells from blood, likely due to a
common ectodermal germ layer origin (Kim et al., 2011).
Another important factor to consider is the reprogramming
efficiency of each cell type. Maintained expression of key
reprogramming factors enhances the frequency of successful
reprogramming significantly. For example, keratinocytes can be
reprogrammed to pluripotent cells at much higher frequency and
a faster rate than fibroblasts from the same biopsy sample, likely
due to greater existing Klf4 and c-Myc expression (Colman and
Dreesen, 2009). This underscores the importance of selecting
the appropriate starting cell type for SCI treatment balancing
epigenetics, ease of harvesting, and the intended final product.
Below we described the most commonly employed cells of origin
and discuss in greater detail their advantages and disadvantages
(Figure 1).
Skin Fibroblasts
Skin fibroblasts are one of the most commonly used cell
sources for reprogramming. Adult human fibroblasts can be
easily obtained, purified, and maintained in culture (Maherali
et al., 2008; Chen et al., 2013a) which is ideal for autologous
transplantation in patients with SCI. However, skin fibroblast
reprogramming to iPSCs is lengthy due to low reprogramming
efficiency. Three to four weeks are required for the amplification
of the fibroblasts derived from a human skin biopsy (Park et al.,
2008) and another 3–4 weeks for iPSC colonies to appear (Park
et al., 2008). After 2 months in culture, only ∼0.01% of adult
human skin fibroblasts become iPSCs if the four Yamanaka
factors are used and this number drops further if three or fewer
factors are employed (Huangfu et al., 2008). Yamanaka suggested
that fibroblasts, as terminally differentiated cells, required much
more aggressive reprogramming than less differentiated cells
(Yamanaka, 2009) increasing the cost (i.e., hands-on time and
reagents) and putting the cells at greater risk of mutation due to
a longer time in culture.
Keratinocytes
Keratinocytes have emerged as a promising cell source for
reprogramming because they can be easily accessed via a small
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skin biopsy or plucked hair (Aasen and Izpisúa Belmonte, 2010)
making the generation of autologous iPSCs easier for future
clinical trials. Keratinocytes do requiremore time than fibroblasts
to expand but they can be reprogrammedmuch more quickly (10
days) and with greater efficiency (Aasen et al., 2008). The higher
reprogramming efficiency of keratinocytes is mainly due to the
higher basal levels of Klf4 and c-Myc (Aasen et al., 2008).
Melanocytes
Similarly, melanocytes can also be isolated from skin biopsies.
Melanocytes contain high levels of endogenous Sox2 and
therefore only require the other three factors for reprogramming
(Utikal et al., 2009). Furthermore, only 10 days in culture are
needed for melanocytes to be reprogrammed and they have
shown a reprogramming efficiency of 0.19% (Utikal et al., 2009).
All of this suggests that melanocytes may be a viable option
as a cell source for autologous iPSC transplants when they are
needed very quickly. However, it remains unknown whether
melanocyte-derived iPSCs can be differentiated to NPCs, what
the differentiation potential of these NPCs would be and whether
they may be used in SCI.
Cord Blood Cells
Umbilical cord blood has been used to generate iPSCs because
the source tissue is often discarded postpartum otherwise and
there are many umbilical cord blood banks around the world
containing potentially autologous (or 1st degree relative) cells.
These cells can be cryopreserved for prolonged periods and have
been shown to maintain their ability to generate iPSCs for many
years (Giorgetti et al., 2009, 2). CD133+ cells from umbilical
cord blood can be reprogrammed to iPSCs by using as few as
two factors (Oct4 and SOX2) with a reprogramming efficiency
of 0.45% (Giorgetti et al., 2009, 2). Cells isolated from umbilical
cord blood are in a primitive state and are therefore ideal for
reprogramming due to their epigenetic signature as they may be
closer than other differentiated cells to the pluripotent state (Red-
Horse et al., 2004). However, the disadvantage of iPSCs from the
umbilical cord is that their preferred differentiation lineages may
notmatchwhat is required for CNS regeneration as they originate
in a different germ cell layer.
CD34+ Cells
Cells expressing CD34 are typically found in bone marrow
and umbilical cord blood and have been used successfully to
generate human iPSCs (Loh et al., 2009). Several populations
of blood-borne CD34+ cells exist in small numbers including
hematopoietic stem cells, B-cell precursors, and megakaryocytes
(Sidney et al., 2014). Unfortunately, the number of these cells
in circulation at any one time tends to be quite low, often
necessitating the use of granulocyte-colony stimulating factor
(G-CSF) stimulation of bone marrow (Loh et al., 2009). While
well-studied and commonly used in patients after chemotherapy,
G-CSF is associated with its own complications including rashes,
fever, fatigue, splenomegaly, and allergic reactions (Brockmann
et al., 2013) which may be significant for patients with SCI. The
reprogramming of CD34+ cells is also inefficient at 0.01–0.02%
with the Yamanaka Factors (Loh et al., 2009). This efficiency
further drops for CD34+ cells isolated from umbilical cord
blood (Ramos-Mejía et al., 2012) making the utility of CD34+
reprogramming for clinical use controversial.
Adipose Tissue Derived Stem Cells
Fat-derived stem cells are abundantly available after liposuction
procedures (Bunnell et al., 2008). As many as 100 million cells
can be isolated from a 300mL sample and can be expanded for
reprogramming in ∼48 h (Sun et al., 2009). Using Yamanaka
Factors, adipose tissue stem cells can be reprogrammed in 10–15
days with an efficiency of 0.2% (Sun et al., 2009). Furthermore,
these cells have high intrinsic levels of Klf4 and their multipotent
nature may mean they require fewer epigenetic changes to reach
pluripotency (Qu et al., 2012). This has made fat-derived stem
cells an exciting area of research for the generation of iPSCs.
DIFFERENTIATED iPSCS FOR SCI
After generation of iPSCs, the cells must be differentiated to the
appropriate multipotent or fully differentiated cell type for the
treatment of SCI. If left in an undifferentiated state, there may
exist a risk of teratoma formation due to the ability of these
rapidly dividing cells to become all three germ layers in situ.
In fact, incomplete differentiation and/or purification to remove
undifferentiated cells is one of the biggest safety concerns with
clinical translation of iPSC-derived therapies for SCI. Our lab and
others have developed techniques to generate safe and effective
monoclonal NPCs from iPSCs using non-viral methods. These
cells have also been shown to survive in animal models of
SCI without evidence of tumor formation or hyperproliferation
(Tropepe et al., 2001; Smukler et al., 2006; Rowland et al., 2011;
Chaddah et al., 2012).
Below we review the most clinically-relevant iPSC-derived cell
types being used in preclinical research (Figure 2).
iPSC-Derived NPCs
NPCs are one of the most promising cell types that have been
studied thus far in the treatment of SCI due to their ability to
replace lost circuits as neurons, remyelinate axons as glia, and
provide local trophic support (Tsuji et al., 2010; Nori et al., 2011;
Kobayashi et al., 2012). Several protocols have been developed
to differentiate iPSCs to NPCs effectively such as dual SMAD
inhibition (Chambers et al., 2013) or embryoid body formation
followed by differentiation into neural rosettes (Muratore et al.,
2014). NPCs can also be generated directly from somatic cells
without an intermediate pluripotent state. The Wernig lab is a
pioneer in generating directly reprogrammed NPCs (drNPCs)
by using Sox2, FoxG1, and Brn2 reprogramming factors (Lujan
et al., 2012). Several other combinations of factors that can
directly reprogram somatic cells to NPCs have subsequently been
discovered (Han et al., 2012; Ring et al., 2012; Zou et al., 2014).
In our laboratory, we have recently been able to generate
definitive NPCs utilizing non-viral piggyBac transposon-induced
iPSCs and induction of the notch pathway. We have shown that
this method is safe and effective (Salewski et al., 2013) and the
resulting autologous iPSC-NPCs could be transplanted into a
thoracic (T6-level) clip-contusionmodel of SCI inmice (Salewski
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FIGURE 2 | Transplantation of iPSC derived cells can target different pathophysiological aspects of spinal cord injury. After injury, spinal cord experiences
inflammation, demyelination, and formation of cystic cavity, glial and fibrotic scaring, axonal degeneration and neural cell death, and disruption of blood spinal cord
barrier BSCB. iPSC derived cells can replace the lost neurons, oligodendrocyte, and astrocytes. They can promote demyelination, modulate the immune response
and also promote the BSCB healing.
et al., 2015). Interestingly, the transplanted cells integrated well
with host tissue and differentiated primarily to remyelinating
oligodendrocytes (59%). This resulted in significant functional
recovery of locomotion as assessed by open field gait analyses
(Salewski et al., 2015). Other studies using iPSC-NPCs in rodents
and primate models of SCI have also found that transplanted
cells can differentiate into neurons and glia in vivo resulting in
enhanced remyelination, axon regeneration, tissue sparing, and
behavioral outcomes (Fujimoto et al., 2012; Kobayashi et al.,
2012; Nutt et al., 2013).
These effects are not limited to the site of transplant. A key
study has shown that iPSC-NPCs transplanted into the spinal
cord parenchyma of NOD-SCID mice can migrate significant
distances (Fujimoto et al., 2012). The neurons derived from
these cells were able to integrate into the host tissue and most
commonly acted as interneurons forming synapses to reconstruct
local neuronal circuits. This study validated hiPSCs-NPCs as a
translationally-relevant neural cell source for preclinical research
and was an important step toward clinical use.
In a 2016 study by Tuszynski lab, iPSC- and ESC-derived
NPCs with a spinal cord specific identity were generated and
transplanted. This study found that cells with a spinal cord
identity effectively promoted corticospinal tract regeneration and
contributed to functional recovery better than classically-derived
NPCs which express markers of brain identity (Kadoya et al.,
2016). This studies further highlights the importance of matching
the identity of transplanted cells with the niche of the host tissue.
iPSC Derived Neurons
Although transplantation of mature neurons into the spinal
cord has typically resulted in poor integration and plasticity
of transplanted cells as compared to neural progenitors, this is
still a growing area of research requiring further optimization.
iPSCs have been differentiated to several types of functional
neurons including dopaminergic neurons (Zhang et al., 2013;
Hallett et al., 2015), cerebral cortical neurons (Shi et al., 2012a,b),
motor-neurons (MN)s (Sareen et al., 2013), and GABAergic
interneurons (Nicholas et al., 2013). In SCI, there is major loss
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of motorneruons and interneruons and although transplantation
of neurons with a cerebral cortical identity (Shi et al., 2012a,b) has
beneficial effects, it is speculated that transplantation of neurons
which possess a spinal cord regional identity can more effectively
engraft into the spinal cord neural circuitry. In a recent study
by Fandel et al. transplantation of stem cell-derived GABAergic
interneurons (Fandel et al., 2016) into the lumbar cord at 2
weeks after thoracic SCI resulted in synaptic connections within
the local circuitry and alleviated long-term neurogenic bladder
dysfunction and neuropathic pain. Stem cell-derived motor
neurons are increasingly being used for cellular replacement
strategies in SCI. Motor neurons (MNs) and motor neurons
precursor cells (MNPs) have successfully been generated from
iPSCs and their use is particularly exciting as this key population
of cells is required in small numbers to effect significant
functional benefit (Sareen et al., 2013). Several protocols have
been established for the generation of MNs from iPSCs. Some
force the expression of MN specific factors (neurogenin 2, islet-
1, and LIM/homeobox protein 3) in iPSCs derived from human
fibroblasts while others rely on caudalization and centralization
morphogens to generateMNPs (Jha et al., 2015). Other successful
protocols have used a combination of reprogramming factors and
growth factors such as GDNF, BDNF, and CNTF to produceMNs
efficiently (Karumbayaram et al., 2009).
iPSC Derived Astrocytes
After SCI, both gray and white matter astrocytes are lost over
a distance of several millimeters. Although reactive astrocytes
proliferate, form a glial scar, and secrete inhibitory agents such
as CSPG, there have been reports that during the first weeks after
injury reactive astrocytes actually protect tissue and contribute
to some of the initial spontaneous recovery in patients. This
likely stems from astrocytes’ capacity to form a barrier around
the lesion epicenter thereby containing infiltrating peripheral
inflammatory cells through the compromised blood-spinal cord
barrier and limiting the spread of the secondary injury cascade
(Faulkner et al., 2004; Renault-Mihara et al., 2008). Furthermore,
transplanted cells that differentiate to immature astrocytes may
facilitate axon regeneration by providing trophic support and
depositing structural extracellular matrix proteins (Tsuji et al.,
2010). In fact, transplantation of purified astrocytes has been
shown to promote axonal regeneration and functional recovery
following acute transection injuries of the adult rat spinal cord
(Davies et al., 2006). Similarly, other studies using iPSC-derived
astrocytes have found that they can not only survive in the harsh
post-injury environment but can produce improvements in the
animals’ sensory recovery (Hayashi et al., 2011). As a result,
further work needs to be completed to determine if the spectrum
of effects produce by astrocytes are a multimodal dose-response
curve or the result of specific subpopulations of “good” and “bad”
astrocytes.
iPSC-Derived Perivascular Stromal Cells
Recently, our lab has shown that human fetal cadaveric
perivascular stromal cells (pericytes) derived from the central
nervous system (CNS-PSCs) have unique immunoregulatory
functions that can reduce peripheral inflammatory cell
infiltration and the permeability of the blood-spinal cord
barrier after early intravenous injection (Badner et al., 2016). The
disadvantage of CNS-PSCs is that they are not easily accessible
and have a limited capacity to proliferate which limits their
therapeutic efficacy. However, CNS-PSCs have been successfully
generated from iPSCs and can potentially expand indefinitely
without senescence (Quattrocelli et al., 2011; Orlova et al., 2014).
Future studies can explore the potential of iPS-CNS-PSCs to
improve behavioral outcomes after SCI.
CHALLENGES AND RECENT PROGRESS
FOR iPSC DERIVED CELLS
In the decade since iPS technology was established, substantial
progress has been made in developing safer and more efficient
reprograming techniques, however, a few key challenges remain
such as tumorigenicity and host immune rejection. Different
inductionmethods can increase the rate of de novomutations and
chromosomal instability which raises the risk of tumorigenicity
(Gore et al., 2011; Ji et al., 2012). It will be important to
limit the level of mutagenesis to an acceptable limit prior to
clinical use. Furthermore, undifferentiated iPSCs themselves or
dedifferentiation of the cells pose a risk of teratoma formation.
For this reason, efficient techniques to differentiate cells prior
to transplantation, and remove potentially harmful cells after
transplantation, will be important (Chen et al., 2013b). Several
approaches are currently being developed for this purpose
including in vitro removal of high proliferation rate cells,
antibodies specifically targeting high-risk subpopulations (e.g.,
potentially teratoma-forming cells), and selective in vivo ablation
of transplanted cells using suicide genes (Wu et al., 2014).
Immunogenicity is a concern with any cell therapy, however,
the distinct advantages of iPSCs is their potential as an autologous
source to reduce or eliminate immune rejection. In theory,
autologous iPSCs derived from a non-invasive sampling of the
patients’ cells should avoid rejection by expressing markers
of “self ” with greater compatibility than any generally well-
accepted allograft (e.g., group-matched blood). Importantly,
this remains theoretical as human trials have yet to be
conducted with autologous iPSCs. It will also be important to
monitor changes in the expression pattern and level of the
genes due to aberrant DNA methylation during reprograming
process which could potentially evoke an immune responses
in transplant recipients even when autologously derived (Zhao
et al., 2011; Araki et al., 2013; Guha et al., 2013). If this is
unavoidable, minor immunogenicity may be addressed using
conventional immunosuppressives or short term monoclonal
antibody-mediated co-stimulation/adhesion blockade of host T
cells (Scheiner et al., 2014). As the technology develops, these risk
and benefits, as well as new challenges, are likely to come to the
forefront.
FUTURE DIRECTIONS
Stem cell transplantation for SCI is an attractive therapeutic
strategy as the grafts offer multiple mechanisms to enhance
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recovery from this multifaceted disease process. Numerous
preclinical studies have generated excitement around the use of
iPSC-derived approaches with the added benefit of potentially
generating autologous cells in the future (Wilcox et al., 2014). A
limited number of clinical trials for the treatment of SCI using
harvested stem cells have been performed in North America but
none have yet used iPSC-derived cells. While the path to clinical
translation has commenced, including the establishment of good
manufacturing practices and animal-free media solutions, there
are several major challenges that need to be further studied at
the preclinical stage. These include the need to better understand
the influence of epigenetics on iPSC-derived progeny and more
refined techniques for differentiation/purification of cell lines.
Furthermore, we require a deeper understanding of the graft-host
microenvironmental interaction in SCI to tailor cell therapies to
the recipient niche for maximal efficacy. Given the tremendous
excitement around this technology, we foresee these challenges
being overcome within the next several years to provide an
effective regenerative therapy to patients with SCI.
AUTHOR CONTRIBUTIONS
MK and CA: Literature review, manuscript writing, editing, and
finalizing, approval of final manuscript. MF: Framing the concept
and structure of the review, editing, and finalizing, approval of
final manuscript.
FUNDING
MF is supported by the Gerry and Tootsie Halbert Chair in
Neural Repair and Regeneration and the DeZwirek Family
Foundation.
REFERENCES
Aasen, T., and Izpisúa Belmonte, J. C. (2010). Isolation and cultivation of
human keratinocytes from skin or plucked hair for the generation of
induced pluripotent stem cells. Nat. Protoc. 5, 371–382. doi: 10.1038/nprot.
2009.241
Aasen, T., Raya, A., Barrero, M. J., Garreta, E., Consiglio, A., Gonzalez, F., et al.
(2008). Efficient and rapid generation of induced pluripotent stem cells from
human keratinocytes. Nat. Biotechnol. 26, 1276–1284. doi: 10.1038/nbt.1503
Ahuja, C. S., and Fehlings, M. (2016). Concise review: bridging the gap: novel
neuroregenerative and neuroprotective strategies in spinal cord injury. Stem
Cells Transl. Med. 5, 914–924. doi: 10.5966/sctm.2015-0381
Ahuja, C. S., Martin, A. R., and Fehlings, M. (2016). Recent advances in managing
a spinal cord injury secondary to trauma. F1000Res. 5:F1000 Faculty Rev-1017.
doi: 10.12688/f1000research.7586.1
Araki, R., Uda, M., Hoki, Y., Sunayama, M., Nakamura, M., Ando, S., et al.
(2013). Negligible immunogenicity of terminally differentiated cells derived
from induced pluripotent or embryonic stem cells. Nature 494, 100–104.
doi: 10.1038/nature11807
Badner, A., Vawda, R., Laliberte, A., Hong, J., Mikhail, M., Jose, A., et al. (2016).
Early intravenous delivery of human brain stromal cells modulates systemic
inflammation and leads to vasoprotection in traumatic spinal cord injury. Stem
Cells Transl. Med. 5, 991–1003. doi: 10.5966/sctm.2015-0295
Ban, H., Nishishita, N., Fusaki, N., Tabata, T., Saeki, K., Shikamura, M., et al.
(2011). Efficient generation of transgene-free human induced pluripotent stem
cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad.
Sci. U.S.A. 108, 14234–14239. doi: 10.1073/pnas.1103509108
Brockmann, F., Kramer, M., Bornhäuser, M., Ehninger, G., and Hölig, K. (2013).
Efficacy and side effects of granulocyte collection in healthy donors. Transfus.
Med. Hemother. 40, 258–264. doi: 10.1159/000354093
Bunnell, B. A., Flaat, M., Gagliardi, C., Patel, B., and Ripoll, C. (2008). Adipose-
derived stem cells: isolation, expansion and differentiation. Methods 45,
115–120. doi: 10.1016/j.ymeth.2008.03.006
Chaddah, R., Arntfield, M., Runciman, S., Clarke, L., and van der Kooy, D.
(2012). Clonal neural stem cells from human embryonic stem cell colonies. J.
Neurosci. Off. J. Soc. Neurosci. 32, 7771–7781. doi: 10.1523/JNEUROSCI.3286-
11.2012
Chambers, S. M., Mica, Y., Lee, G., Studer, L., and Tomishima, M. J. (2013). “Dual-
SMAD inhibition/WNT activation-based methods to induce neural crest and
derivatives from human pluripotent stem cells,” inHuman Embryonic Stem Cell
Protocols, ed K. Turksen (New York, NY: Springer), 329–343. Available online
at: http://link.springer.com/10.1007/7651_2013_59 (Accessed June 9, 2016).
Chen, J., Lin, M., Foxe, J. J., Pedrosa, E., Hrabovsky, A., Carroll, R., et al. (2013a).
Transcriptome comparison of human neurons generated using induced
pluripotent stem cells derived from dental pulp and skin fibroblasts. PLoS ONE
8:e75682. doi: 10.1371/journal.pone.0075682
Chen, J., Liu, H., Liu, J., Qi, J., Wei, B., Yang, J., et al. (2013b). H3K9 methylation is
a barrier during somatic cell reprogramming into iPSCs. Nat. Genet. 45, 34–42.
doi: 10.1038/ng.2491
Chen, Y., McGee, J., Chen, X., Doman, T. N., Gong, X., Zhang, Y., et al. (2014).
Identification of druggable cancer driver genes amplified across TCGA datasets.
PLoS ONE 9:e98293. doi: 10.1371/journal.pone.0098293
Choo, A. M., Liu, J., Lam, C. K., Dvorak, M., Tetzlaff, W., and Oxland, T. R. (2007).
Contusion, dislocation, and distraction: primary hemorrhage and membrane
permeability in distinct mechanisms of spinal cord injury. J. Neurosurg. Spine
6, 255–266. doi: 10.3171/spi.2007.6.3.255
Colman, A., and Dreesen, O. (2009). Pluripotent stem cells and disease modeling.
Cell Stem Cell 5, 244–247. doi: 10.1016/j.stem.2009.08.010
Davies, J. E., Huang, C., Proschel, C., Noble, M., Mayer-Proschel, M., and Davies, S.
J. A. (2006). Astrocytes derived from glial-restricted precursors promote spinal
cord repair. J. Biol. 5, 7. doi: 10.1186/jbiol35
Fandel, T. M., Trivedi, A., Nicholas, C. R., Zhang, H., Chen, J., Martinez, A. F.,
et al. (2016). Transplanted human stem cell-derived interneuron precursors
mitigate mouse bladder dysfunction and central neuropathic pain after spinal
cord injury. Cell Stem Cell 19, 544–557. doi: 10.1016/j.stem.2016.08.020
Faulkner, J. R., Herrmann, J. E., Woo, M. J., Tansey, K. E., Doan, N. B., and
Sofroniew, M. V. (2004). Reactive astrocytes protect tissue and preserve
function after spinal cord injury. J. Neurosci. Off. J. Soc. Neurosci. 24,
2143–2155. doi: 10.1523/JNEUROSCI.3547-03.2004
Fujimoto, Y., Abematsu, M., Falk, A., Tsujimura, K., Sanosaka, T., Juliandi,
B., et al. (2012). Treatment of a mouse model of spinal cord injury
by transplantation of human induced pluripotent stem cell-derived long-
term self-renewing neuroepithelial-like stem cells. Stem Cells 30, 1163–1173.
doi: 10.1002/stem.1083
Giorgetti, A., Montserrat, N., Aasen, T., Gonzalez, F., Rodríguez-Pizà, I.,
Vassena, R., et al. (2009). Generation of induced pluripotent stem cells
from human cord blood using OCT4 and SOX2. Cell Stem Cell 5, 353–357.
doi: 10.1016/j.stem.2009.09.008
Gore, A., Li, Z., Fung, H.-L., Young, J. E., Agarwal, S., Antosiewicz-Bourget, J.,
et al. (2011). Somatic coding mutations in human induced pluripotent stem
cells. Nature 471, 63–67. doi: 10.1038/nature09805
Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., and Boyd, A.
S. (2013). Lack of immune response to differentiated cells derived from
syngeneic induced pluripotent stem cells. Cell Stem Cell 12, 407–412.
doi: 10.1016/j.stem.2013.01.006
Hallett, P. J., Deleidi, M., Astradsson, A., Smith, G. A., Cooper, O., Osborn, T. M.,
et al. (2015). Successful function of autologous iPSC-derived dopamine neurons
following transplantation in a non-human primate model of Parkinson’s
Disease. Cell Stem Cell 16, 269–274. doi: 10.1016/j.stem.2015.01.018
Han, D. W., Tapia, N., Hermann, A., Hemmer, K., Höing, S., Araúzo-Bravo, M.
J., et al. (2012). Direct reprogramming of fibroblasts into neural stem cells by
defined factors. Cell Stem Cell 10, 465–472. doi: 10.1016/j.stem.2012.02.021
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 January 2017 | Volume 4 | Article 152
Khazaei et al. iPSCs for Spinal Cord Injury
Hayashi, K., Hashimoto, M., Koda, M., Naito, A. T., Murata, A., Okawa, A., et al.
(2011). Increase of sensitivity to mechanical stimulus after transplantation of
murine induced pluripotent stem cell-derived astrocytes in a rat spinal cord
injury model. J. Neurosurg. Spine 15, 582–593. doi: 10.3171/2011.7.SPINE10775
Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.
E., et al. (2008). Induction of pluripotent stem cells by defined factors is
greatly improved by small-molecule compounds. Nat. Biotechnol. 26, 795–797.
doi: 10.1038/nbt1418
Jha, B. S., Rao, M., and Malik, N. (2015). Motor neuron differentiation from
pluripotent stem cells and other intermediate proliferative precursors that can
be discriminated by lineage specific reporters. Stem Cell Rev. 11, 194–204.
doi: 10.1007/s12015-014-9541-0
Ji, J., Ng, S. H., Sharma, V., Neculai, D., Hussein, S., Sam, M., et al. (2012). Elevated
coding mutation rate during the reprogramming of human somatic cells into
induced pluripotent stem cells. Stem Cells 30, 435–440. doi: 10.1002/stem.1011
Kadoya, K., Lu, P., Nguyen, K., Lee-Kubli, C., Kumamaru, H., Yao, L., et al. (2016).
Spinal cord reconstitution with homologous neural grafts enables robust
corticospinal regeneration. Nat. Med. 22, 479–487. doi: 10.1038/nm.4066
Karumbayaram, S., Novitch, B. G., Patterson, M., Umbach, J. A., Richter,
L., Lindgren, A., et al. (2009). Directed differentiation of human-induced
pluripotent stem cells generates active motor neurons. Stem Cells 27, 806–811.
doi: 10.1002/stem.31
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S.,
et al. (2009). Generation of human induced pluripotent stem cells by
direct delivery of reprogramming proteins. Cell Stem Cell 4, 472–476.
doi: 10.1016/j.stem.2009.05.005
Kim, K., Zhao, R., Doi, A., Ng, K., Unternaehrer, J., Cahan, P., et al. (2011).
Donor cell type can influence the epigenome and differentiation potential
of human induced pluripotent stem cells. Nat. Biotechnol. 29, 1117–1119.
doi: 10.1038/nbt.2052
Kobayashi, Y., Okada, Y., Itakura, G., Iwai, H., Nishimura, S., Yasuda, A., et al.
(2012). Pre-evaluated safe human iPSC-derived neural stem cells promote
functional recovery after spinal cord injury in common marmoset without
tumorigenicity. PLoS ONE 7:e52787. doi: 10.1371/journal.pone.0052787
LaPlaca, M. C., Simon, C. M., Prado, G. R., and Cullen, D. K. (2007). CNS
injury biomechanics and experimental models. Prog. Brain Res. 161, 13–26.
doi: 10.1016/S0079-6123(06)61002-9
Loh, Y.-H., Agarwal, S., Park, I.-H., Urbach, A., Huo, H., Heffner, G. C., et al.
(2009). Generation of induced pluripotent stem cells from human blood. Blood
113, 5476–5479. doi: 10.1182/blood-2009-02-204800
Lujan, E., Chanda, S., Ahlenius, H., Südhof, T. C., and Wernig, M.
(2012). Direct conversion of mouse fibroblasts to self-renewing, tripotent
neural precursor cells. Proc. Natl. Acad. Sci. U.S.A. 109, 2527–2532.
doi: 10.1073/pnas.1121003109
Maherali, N., Ahfeldt, T., Rigamonti, A., Utikal, J., Cowan, C., and Hochedlinger,
K. (2008). A high-efficiency system for the generation and study of
human induced pluripotent stem cells. Cell Stem Cell 3, 340–345.
doi: 10.1016/j.stem.2008.08.003
Mautes, A. E. M., Weinzierl, M. R., Donovan, F., and Noble, L. J. (2000). Vascular
events after spinal cord injury: contribution to secondary pathogenesis. Phys.
Ther. 80, 673–687. doi: 10.1093/ptj/80.7.673
Meng, X., Neises, A., Su, R.-J., Payne, K. J., Ritter, L., Gridley, D. S., et al. (2012).
Efficient reprogramming of human cord blood CD34+ cells into induced
pluripotent stem cells with OCT4 and SOX2 Alone. Mol. Ther. 20, 408–416.
doi: 10.1038/mt.2011.258
Muratore, C. R., Srikanth, P., Callahan, D. G., and Young-Pearse, T.
L. (2014). Comparison and optimization of hiPSC forebrain cortical
differentiation protocols. PLoS ONE 9:e105807. doi: 10.1371/journal.pone.
0105807
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., et al.
(2008). Generation of induced pluripotent stem cells without Myc from mouse
and human fibroblasts. Nat. Biotechnol. 26, 101–106. doi: 10.1038/nbt1374
National Spinal Cord Injury Statistical Center (2014). Spinal cord injury
facts and figures at a glance. J. Spinal Cord Med. 37, 355–356.
doi: 10.1179/1079026814Z.000000000260
Nicholas, C. R., Chen, J., Tang, Y., Southwell, D. G., Chalmers, N., Vogt, D.,
et al. (2013). Functional maturation of hPSC-derived forebrain interneurons
requires an extended timeline and mimics human neural development. Cell
Stem Cell 12, 573–586. doi: 10.1016/j.stem.2013.04.005
Nori, S., Okada, Y., Yasuda, A., Tsuji, O., Takahashi, Y., Kobayashi, Y., et al. (2011).
Grafted human-induced pluripotent stem-cell–derived neurospheres promote
motor functional recovery after spinal cord injury in mice. Proc. Natl. Acad. Sci.
U.S.A. 108, 16825–16830. doi: 10.1073/pnas.1108077108
Nutt, S. E., Chang, E.-A., Suhr, S. T., Schlosser, L. O., Mondello, S. E., Moritz, C. T.,
et al. (2013). Caudalized human iPSC-derived neural progenitor cells produce
neurons and glia but fail to restore function in an early chronic spinal cord
injury model. Exp. Neurol. 248, 491–503. doi: 10.1016/j.expneurol.2013.07.010
Orlova, V. V., Drabsch, Y., Freund, C., Petrus-Reurer, S., van den Hil, F.
E., Muenthaisong, S., et al. (2014). Functionality of endothelial cells and
pericytes from human pluripotent stem cells demonstrated in cultured vascular
plexus and zebrafish xenografts. Arterioscler. Thromb. Vasc. Biol. 34, 177–186.
doi: 10.1161/ATVBAHA.113.302598
Park, I.-H., Lerou, P. H., Zhao, R., Huo, H., and Daley, G. Q. (2008). Generation
of human-induced pluripotent stem cells. Nat. Protoc. 3, 1180–1186.
doi: 10.1038/nprot.2008.92
Qu, X., Liu, T., Song, K., Li, X., and Ge, D. (2012). Induced pluripotent
stem cells generated from human adipose-derived stem cells using a non-
viral polycistronic plasmid in feeder-free conditions. PLoS ONE 7:e48161.
doi: 10.1371/journal.pone.0048161
Quattrocelli, M., Palazzolo, G., Floris, G., Schöffski, P., Anastasia, L.,
Orlacchio, A., et al. (2011). Intrinsic cell memory reinforces myogenic
commitment of pericyte-derived iPSCs. J. Pathol. 223, 593–603. doi: 10.1002/
path.2845
Ramos-Mejía, V., Montes, R., Bueno, C., Ayllón, V., Real, P. J., Rodríguez,
R., et al. (2012). Residual expression of the reprogramming factors prevents
differentiation of iPSC generated from human fibroblasts and cord blood
CD34+ progenitors. PLoS ONE 7:e35824. doi: 10.1371/journal.pone.00
35824
Red-Horse, K., Zhou, Y., Genbacev, O., Prakobphol, A., Foulk, R., McMaster,
M., et al. (2004). Trophoblast differentiation during embryo implantation
and formation of the maternal-fetal interface. J. Clin. Invest. 114, 744–754.
doi: 10.1172/JCI200422991
Renault-Mihara, F., Okada, S., Shibata, S., Nakamura, M., Toyama, Y.,
and Okano, H. (2008). Spinal cord injury: emerging beneficial role of
reactive astrocytes’ migration. Int. J. Biochem. Cell Biol. 40, 1649–1653.
doi: 10.1016/j.biocel.2008.03.009
Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y., Li,
G., et al. (2012). Direct reprogramming of mouse and human fibroblasts into
multipotent neural stem cells with a single factor. Cell Stem Cell 11, 100–109.
doi: 10.1016/j.stem.2012.05.018
Rowland, J. W., Lee, J. J., Salewski, R. P., Eftekharpour, E., van der Kooy, D., and
Fehlings, M. G. (2011). Generation of neural stem cells from embryonic stem
cells using the default mechanism: in vitro and in vivo characterization. Stem
Cells Dev. 20, 1829–1845. doi: 10.1089/scd.2011.0214
Salewski, R. P., Buttigieg, J., Mitchell, R. A., van der Kooy, D., Nagy, A., and
Fehlings, M. G. (2013). The generation of definitive neural stem cells from
PiggyBac transposon-induced pluripotent stem cells can be enhanced by
induction of the NOTCH signaling pathway. Stem Cells Dev. 22, 383–396.
doi: 10.1089/scd.2012.0218
Salewski, R. P., Mitchell, R. A., Li, L., Shen, C., Milekovskaia, M., Nagy,
A., et al. (2015). Transplantation of induced pluripotent stem cell-derived
neural stem cells mediate functional recovery following thoracic spinal cord
injury through remyelination of axons. Stem Cells Transl. Med. 4, 743–754.
doi: 10.5966/sctm.2014-0236
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S.,
Simpkinson, M., et al. (2013). Targeting RNA foci in iPSC-derived motor
neurons fromALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med.
5, 208ra149. doi: 10.1126/scitranslmed.3007529
Scheiner, Z. S., Talib, S., and Feigal, E. G. (2014). The potential for immunogenicity
of autologous induced pluripotent stem cell-derived therapies. J. Biol. Chem.
289, 4571–4577. doi: 10.1074/jbc.R113.509588
Shi, Y., Kirwan, P., and Livesey, F. J. (2012a). Directed differentiation of human
pluripotent stem cells to cerebral cortex neurons and neural networks. Nat.
Protoc. 7, 1836–1846. doi: 10.1038/nprot.2012.116
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 January 2017 | Volume 4 | Article 152
Khazaei et al. iPSCs for Spinal Cord Injury
Shi, Y., Kirwan, P., Smith, J., Robinson, H. P. C., and Livesey, F. J. (2012b).
Human cerebral cortex development from pluripotent stem cells to functional
excitatory synapses. Nat. Neurosci. 15, 477–486. doi: 10.1038/nn.3041
Sidney, L. E., Branch, M. J., Dunphy, S. E., Dua, H. S., and Hopkinson, A.
(2014). Concise review: evidence for CD34 as a common marker for diverse
progenitors. Stem Cells 32, 1380–1389. doi: 10.1002/stem.1661
Smukler, S. R., Runciman, S. B., Xu, S., and van der Kooy, D. (2006). Embryonic
stem cells assume a primitive neural stem cell fate in the absence of extrinsic
influences. J. Cell Biol. 172, 79–90. doi: 10.1083/jcb.200508085
Subramanyam, D., Lamouille, S., Judson, R. L., Liu, J. Y., Bucay, N., Derynck, R.,
et al. (2011).Multiple targets of miR-302 andmiR-372 promote reprogramming
of human fibroblasts to induced pluripotent stem cells. Nat. Biotechnol. 29,
443–448. doi: 10.1038/nbt.1862
Sun, N., Panetta, N. J., Gupta, D. M., Wilson, K. D., Lee, A., Jia, F., et al.
(2009). Feeder-free derivation of induced pluripotent stem cells from adult
human adipose stem cells. Proc. Natl. Acad. Sci. U.S.A. 106, 15720–15725.
doi: 10.1073/pnas.0908450106
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al.
(2007). Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell 131, 861–872. doi: 10.1016/j.cell.2007.11.019
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126,
663–676. doi: 10.1016/j.cell.2006.07.024
Tetzlaff, W., Okon, E. B., Karimi-Abdolrezaee, S., Hill, C. E., Sparling, J. S., Plemel,
J. R., et al. (2011). A systematic review of cellular transplantation therapies for
spinal cord injury. J. Neurotrauma 28, 1611–1682. doi: 10.1089/neu.2009.1177
Tobias, C. A., Shumsky, J. S., Shibata, M., Tuszynski, M. H., Fischer, I., Tessler, A.,
et al. (2003). Delayed grafting of BDNF and NT-3 producing fibroblasts into
the injured spinal cord stimulates sprouting, partially rescues axotomized red
nucleus neurons from loss and atrophy, and provides limited regeneration. Exp.
Neurol. 184, 97–113. doi: 10.1016/S0014-4886(03)00394-7
Tropepe, V., Hitoshi, S., Sirard, C., Mak, T. W., Rossant, J., and van der Kooy, D.
(2001). Direct neural fate specification from embryonic stem cells: a primitive
mammalian neural stem cell stage acquired through a default mechanism.
Neuron 30, 65–78. doi: 10.1016/S0896-6273(01)00263-X
Tsuji, O., Miura, K., Okada, Y., Fujiyoshi, K., Mukaino, M., Nagoshi, N.,
et al. (2010). Therapeutic potential of appropriately evaluated safe-induced
pluripotent stem cells for spinal cord injury. Proc. Natl. Acad. Sci. U.S.A. 107,
12704–12709. doi: 10.1073/pnas.0910106107
Ulndreaj, A., Chio, J. C. T., Ahuja, C. S., and Fehlings,M. G. (2016).Modulating the
immune response in spinal cord injury. Expert Rev. Neurother. 16, 1127–1129.
doi: 10.1080/14737175.2016.1207532
Utikal, J., Maherali, N., Kulalert, W., and Hochedlinger, K. (2009). Sox2
is dispensable for the reprogramming of melanocytes and melanoma
cells into induced pluripotent stem cells. J. Cell Sci. 122, 3502–3510.
doi: 10.1242/jcs.054783
Vawda, R., Wilcox, J., and Fehlings, M. (2012). Current stem cell treatments for
spinal cord injury. Indian J. Orthop. 46, 10–18. doi: 10.4103/0019-5413.91629
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., et al. (2010).
Highly efficient reprogramming to pluripotency and directed differentiation
of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618–630.
doi: 10.1016/j.stem.2010.08.012
Waxman, S. G. (1989). Demyelination in spinal cord injury. J. Neurol. Sci. 91, 1–14.
doi: 10.1016/0022-510X(89)90072-5
Whetstone, W. D., Hsu, J.-Y. C., Eisenberg, M., Werb, Z., and Noble-Haeusslein,
L. J. (2003). Blood-spinal cord barrier after spinal cord injury: relation
to revascularization and wound healing. J. Neurosci. Res. 74, 227–239.
doi: 10.1002/jnr.10759
Wilcox, J. T., Satkunendrarajah, K., Zuccato, J. A., Nassiri, F., and Fehlings,
M. G. (2014). Neural precursor cell transplantation enhances functional
recovery and reduces astrogliosis in bilateral compressive/contusive cervical
spinal cord injury. Stem Cells Transl. Med. 3, 1148–1159. doi: 10.5966/sctm.
2014-0029
Woltjen, K., Michael, I. P., Mohseni, P., Desai, R., Mileikovsky, M., Hämäläinen,
R., et al. (2009). piggyBac transposition reprograms fibroblasts to induced
pluripotent stem cells. Nature 458, 766–770. doi: 10.1038/nature07863
Wu, C., Hong, S. G., Winkler, T., Spencer, D. M., Jares, A., Ichwan, B.,
et al. (2014). Development of an inducible caspase-9 safety switch for
pluripotent stem cell–based therapies. Mol. Ther. Methods Clin. Dev. 1:14053.
doi: 10.1038/mtm.2014.53
Yamanaka, S. (2009). Elite and stochastic models for induced pluripotent stem cell
generation. Nature 460, 49–52. doi: 10.1038/nature08180
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., et al. (2009).
Human induced pluripotent stem cells free of vector and transgene sequences.
Science 324, 797–801. doi: 10.1126/science.1172482
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.
L., Tian, S., et al. (2007). Induced pluripotent stem cell lines derived
from human somatic cells. Science 318, 1917–1920. doi: 10.1126/science.
1151526
Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., et al. (2013). Rapid
single-step induction of functional neurons from human pluripotent stem cells.
Neuron 78, 785–798. doi: 10.1016/j.neuron.2013.05.029
Zhao, T., Zhang, Z.-N., Rong, Z., and Xu, Y. (2011). Immunogenicity of induced
pluripotent stem cells. Nature 474, 212–215. doi: 10.1038/nature10135
Zhao, Y., Yin, X., Qin, H., Zhu, F., Liu, H., Yang, W., et al. (2008). Two supporting
factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell
3, 475–479. doi: 10.1016/j.stem.2008.10.002
Zhou, W., and Freed, C. R. (2009). Adenoviral gene delivery can reprogram
human fibroblasts to induced pluripotent stem cells. Stem Cells 27, 2667–2674.
doi: 10.1002/stem.201
Zou, Q., Yan, Q., Zhong, J., Wang, K., Sun, H., Yi, X., et al. (2014). Direct
conversion of human fibroblasts into neuronal restricted progenitors. J. Biol.
Chem. 289, 5250–5260. doi: 10.1074/jbc.M113.516112
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Khazaei, Ahuja and Fehlings. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 January 2017 | Volume 4 | Article 152
